Previous Close | 2.7500 |
Open | 2.7600 |
Bid | 2.5100 x 1300 |
Ask | 2.8500 x 1200 |
Day's Range | 2.6600 - 2.8300 |
52 Week Range | 1.2000 - 18.7750 |
Volume | |
Avg. Volume | 132,494 |
Market Cap | 504.32M |
Beta (5Y Monthly) | 1.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3400 |
Earnings Date | Feb 28, 2023 - Mar 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.42 |
BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide a b
BILLERICA, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market (“NASDAQ”) on November 25, 2022 notifying Conformis that, based on the closing bid price of Conformis’ common stock having been $1.00 per share or greater on each of the trading days from November 10, 2022 to November 23, 2022, Conformis has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the
First Actera™ procedure underscores company’s ongoing commitment to advancing joint replacement technology by leveraging its data-driven approach and surgical planning expertiseBILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced that the first procedure with the company’s new Actera™ Hip System has been performed. Dr. William Kurtz, MD performed the hip re